A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood
11 de agosto de 2026 actualizado por: BrainJuice
This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants.
Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
30
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89101
- Citruslabs
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- Be male or female
- Be aged 18-57
- Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease
- If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
- Anyone who is a regular caffeine consumer without a history of caffeine sensitivity or intolerance
- Willing to maintain the same diet and exercise regimen consistently throughout the study duration
- Willing to limit caffeine consumption to one additional serving of caffeine outside of the test product i.e. one cup of brewed coffee (~100 mg), one matcha (~60 mg), two shots of espresso (~120 mg), or one cup of caffeinated tea (~50 mg)
- Resides in the United States
- Has access to a computer or tablet device
Exclusion Criteria:
- Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders
- History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine
- History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder
- History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea
- Anyone with a job that involves shift work that may be overnight or night hours
- Planning on introducing any products or any new forms of prescription medication or supplements that target cognitive function, cognitive performance, or mood, for the study duration
- Anyone with any allergies or sensitivities to any of the study product ingredients
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
- Anyone unwilling to follow the study protocol
- Anyone with a history of substance abuse
- Anyone who is currently a smoker or has been a smoker in the past 3 months
- Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: BrainJuice Supplement
|
All participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6.
There is no comparator or placebo arm.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Cognitive Assessment Score (Polygons)
Periodo de tiempo: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Double Trouble)
Periodo de tiempo: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Feature Match)
Periodo de tiempo: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Paired Associates)
Periodo de tiempo: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Digit Span)
Periodo de tiempo: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Spatial Planning)
Periodo de tiempo: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Self-Reported Focus
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived focus from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Attention
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived attention from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Concentration
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived concentration from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Productivity
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived productivity from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Alertness
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived alertness from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Mental Clarity
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived mental clarity from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Mood
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived mood from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Mental Fatigue
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived mental fatigue from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Motivation
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived motivation from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Organization
Periodo de tiempo: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived organization from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
9 de noviembre de 2025
Finalización primaria (Actual)
6 de febrero de 2026
Finalización del estudio (Actual)
6 de febrero de 2026
Fechas de registro del estudio
Enviado por primera vez
11 de agosto de 2026
Primero enviado que cumplió con los criterios de control de calidad
11 de agosto de 2026
Publicado por primera vez (Actual)
14 de agosto de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
14 de agosto de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
11 de agosto de 2026
Última verificación
1 de agosto de 2026
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 20807 (Otro identificador: Fred Hutch/University of Washington Cancer Consortium)
- legacy-20807
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .